Email HO_Yan_Teck@moh.gov.sg

Dr Ho Yan Teck is a health technology assessment (HTA) and pharmaceutical policy specialist at the Agency for Care Effectiveness (ACE), Ministry of Health, Singapore, where he leads national workstreams on value-based pricing and risk-sharing arrangements for medicines and medical technologies. Over the past decade he has designed Singapore’s frameworks for innovative payment models, negotiated pricing and reimbursement agreements with multinational manufacturers, and led HTAs that shaped national subsidy decisions for drugs and medical technologies. He has represented Singapore in international engagements with the WHO and the Pharmaceutical Pricing and Reimbursement Information (PPRI) network. Yan Teck holds a PhD in Biomedical Engineering from NUS, where his doctoral research focused on cancer nanomedicine. At SSHSPH, he brings this blend of scientific training and hands-on policy experience to teaching on health technology assessment, pricing, and health financing. Outside of work, he enjoys fitness, soccer, programming, and following developments in science and medicine.

• NUS Saw Swee Hock School of Public Health
• Ministry of Health, Singapore, Agency for Care Effectiveness (ACE)

• Health technology assessment (HTA) methodology
• Value-based pricing and innovative payment models
• Managed entry / risk-sharing arrangements
• Pharmaceutical and medical technology pricing policy
• Health financing and reimbursement policy

• Health technology assessment
• Value-based pricing and reimbursement negotiation
• Health systems and policies

• PhD, Biomedical Engineering (Cancer Nanomedicine), NUS Graduate School of Integrative Sciences and Engineering, 2018
• Bachelor of Engineering (First Class Honours), Bioengineering, NUS

• Dux Award, Health Technology Assessment Postgraduate Course, University of Adelaide
• NGS PhD Graduate Scholarship, NUS Graduate School of Integrative Sciences and Engineering
• NUS Research Scholarship
• Dean’s List, B.Eng (Bioengineering) NUS

• Lead Specialist, Value Based Pricing/Risk Sharing Arrangements, Agency for Care Effectiveness (ACE), MOH, Singapore (Apr 2026–present)
• Senior Specialist, Value Based Pricing/Risk Sharing Arrangements, ACE, MOH (Apr 2024–Mar 2026)
• Specialist, Value Based Pricing/Risk Sharing Arrangements, ACE, MOH (Apr 2022–Mar 2024)
• Principal Analyst, Value Based Pricing and Gene Therapy Evaluation, ACE, MOH (Aug 2019–Mar 2022)
• Assistant Head/Senior Officer, CREATE, National Research Foundation, Prime Minister’s Office, Singapore (May 2018–Jul 2019)
• Graduate Researcher, NUS Department of Biomedical Engineering / Singapore-MIT Alliance for Research and Technology (SMART) (Jan 2013–Jan 2018)

• Ho YT, Kamm RD, Kah JCY. Nanoscale. 2018;10:12386–12397. doi:10.1039/C8NR02393J
• Ho YT, Azman NA, Loh FWY, Ong GKT, Engudar G, Kriz SA, Kah JCY. Bioconjugate Chemistry. 2018;29(11). doi:10.1021/acs.bioconjchem.8b00743
• Ho YT, Lee SWL, Azman NA, Loh FWY, Nhan PT, Kah JCY. Langmuir. 2018. doi:10.1021/acs.langmuir.8b00322
• Ho YT, Adriani G, Beyer S, Nhan PT, Kamm RD, Kah JCY. Scientific Reports. 2017;7:707. doi:10.1038/s41598-017-00750-3
• Ho YT, Poinard B, Kah JCY. Nanomedicine. 2016;11:693–714. doi:10.2217/nnm.16.6
• Ho YT, Poinard B, Yeo ELL, Kah JCY. Analyst. 2015;140:1026–1036. doi:10.1039/C4AN01819B
• Kiew SF, Ho YT, Kiew LV, Kah JCY, et al. Int J Pharm. 2017;534:297–307. doi:10.1038/s41598-017-00750-3